| Identification | Back Directory | [Name]
Lasofoxifene | [CAS]
180916-16-9 | [Synonyms]
(5R,6S)-
CP-336,156
Lasofoxifene
Lasofoxifene Base
(5R,6S)-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]tetralin-2-ol
(5R,6S)-5,6,7,8-Tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-naphthalenol
(5R-cis)-5,6,7,8-Tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-naphthalenol
2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- | [Molecular Formula]
C28H31NO2 | [MDL Number]
MFCD09475650 | [MOL File]
180916-16-9.mol | [Molecular Weight]
413.55 |
| Chemical Properties | Back Directory | [Melting point ]
110-113°C | [Boiling point ]
572.4±50.0 °C(Predicted) | [density ]
1.150±0.06 g/cm3(Predicted) | [storage temp. ]
Refrigerator | [solubility ]
Chloroform (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
10.31±0.60(Predicted) | [color ]
White to Off-White |
| Hazard Information | Back Directory | [Chemical Properties]
Off-White Solid | [Uses]
A next-generation selective estrogen receptor modulator for treating disorders associated with increased bone turnover and osteopenia. | [Definition]
ChEBI: Lasofoxifene is a member of the class of tetralins that is 5,6,7,8-tetrahydronaphthalen-2-ol in which the hydrogens at positions 5 and 6 are replaced by 4-[2-(pyrrolidin-1-yl)ethoxy]phenyl and phenyl groups, respectively (the 5R,6S-stereoisomer). It is a selective estrogen receptor modulator indicated for the prevention and treatment of osteoporosis in post-menopausal women. It has a role as an antineoplastic agent, a cardioprotective agent, an estrogen receptor agonist, an estrogen receptor antagonist and a bone density conservation agent. It is a member of tetralins, an aromatic ether, a member of naphthols and a N-alkylpyrrolidine. | [Clinical Use]
Lasofoxifene is a very potent second-generation SERM currently in phase III clinical trials for the treatment and
prevention of osteoporosis in postmenopausal women. |
|
|